

**Supplementary Table 1.** Mean CSF-corrected Metabolite Concentrations at Baseline, Week 2, and 4 in MA dependent Patients Treated with CDP-choline or Placebo

Metabolites		Mean (SD) Concentrations, in mmol/L		Analysis	
		CDP-choline Group (n=16)	Placebo Group (n=15)	z	p value*
Creatine	Baseline	9.31 (1.24)	9.61 (0.97)	0.11	0.91
	Week 2	9.31 (1.27)	9.52 (1.19)		
	Week 4	9.38 (1.18)	9.44 (1.26)		
NAA	Baseline	9.94 (0.91)	9.99 (0.82)	2.79	0.005
	Week 2	10.12 (1.05)	9.76 (0.74)		
	Week 4	10.48 (0.54)	9.69 (0.97)		
Cho	Baseline	2.75 (0.38)	2.77 (0.29)	2.13	0.03
	Week 2	2.79 (0.33)	2.73 (0.28)		
	Week 4	2.85 (0.33)	2.74 (0.30)		
myo-Inositol <sup>†</sup>	Baseline	7.50 (1.25)	7.67 (1.66)	1.18	0.20
	Week 2	7.34 (1.20)	7.57 (1.47)		
	Week 4	7.45 (1.20)	7.59 (1.72)		

CSF, cerebrospinal fluid; NAA, n-acetyl aspartate/n-acetyl aspartyl glutamate; Cho, phosphocholine/glycerophosphocholine; SD, standard deviation.

\*P values were calculated by the F test for the interaction between group and time in generalized estimating equation model. Age, sex, and each metabolite concentration at baseline were included as covariates.

<sup>†</sup>Data were unavailable for 4 participants because of poor reliability of determination.